ICAR's Gene-Edited Rice and GenomeIndia's 10,000 Genomes

India released the world's first government-developed genome-edited rice on 5 May 2025, when the Indian Council of Agricultural Research (ICAR) unveiled two varieties bred with CRISPR-based editing rather than conventional crossing or transgenics.

SDN-1 editing, and why the regulatory status matters

The flagship is DRR Dhan 100 (Kamala), which edits the CKX2/Gn1a gene to raise the number of grains per panicle and mature roughly 20 days earlier. The second, Pusa DST Rice 1, is engineered for drought and salinity tolerance. ICAR's claims for the varieties include an approximately 19% yield gain, around 20% lower greenhouse-gas emissions, and significant irrigation-water savings, the last from shorter crop duration.

The decisive detail is the editing method. Both use SDN-1 editing, which introduces small, targeted changes at a precise genomic site without inserting any foreign DNA. Under India's 2022 rules, SDN-1 and SDN-2 edited crops carrying no foreign genetic material are exempt from the regulatory regime that governs genetically modified organisms. That exemption is the commercial unlock: it removes the multi-year approval bottleneck and political baggage that stalled GM food crops such as Bt brinjal, giving Indian agri-biotech a faster, cheaper route from lab to field.

A sovereign reference genome

In parallel, the GenomeIndia project opened its 10,000 whole-genome dataset, sampled across 83-plus communities, to researchers through the Indian Biological Data Centre. The next target is 10 million genomes.

The strategic value is sovereignty. Most reference genomes used in drug discovery are skewed toward European ancestry, which limits their relevance to Indian patients. A large, India-specific genomic dataset becomes foundational infrastructure for precision medicine and domestic drug-target discovery, and keeping it on national data infrastructure matters for both research access and data governance. Together, gene-edited staples that sidestep GM regulation and a sovereign genomic reference mark a maturing Indian biotech base, one increasingly built on indigenous tools and indigenous data rather than imported platforms.